Product Description: Ruzasvir (MK-8408) is an orally active inhibitor for genotypic HCV nonstructural protein 5A (NS5A), which inhibits the replication of NS5A mutants GT1a, GT1a L31V, GT1a Y93H, GT2b, GT3a and GT4a with EC90 ranging from 0.003 to 0.067 nM. Ruzasvir exhibits good pharmacokinetic characters in rhesus monkey model[1].
Applications: COVID-19-anti-virus
Formula: C49H55FN10O7S
References: [1]Tong L, et al., Discovery of Ruzasvir (MK-8408): A Potent, Pan-Genotype HCV NS5A Inhibitor with Optimized Activity against Common Resistance-Associated Polymorphisms. J Med Chem. 2017 Jan 12;60(1):290-306.
CAS Number: 1613081-64-3
Molecular Weight: 947.09
Compound Purity: 95.82
Research Area: Infection
Solubility: DMSO : 100 mg/mL (ultrasonic)
Target: HCV